Literature DB >> 19340686

Melasma: treatment evaluation.

Ahmed Salem1, Hend Gamil, Ali Ramadan, Mona Harras, Amin Amer.   

Abstract

INTRODUCTION: Melasma is a common disorder of facial hyperpigmentation that can be resistant to treatment. Our purpose is to evaluate the clinical efficacy of the different available modalities of treatment of melasma among Egyptian patients who have mostly skin types IV-V under a sunny climate.
METHODS: A total of 45 patients with moderate-to-severe melasma were subjected to topical application of hydroquinone 4% cream, chemical peeling with 30% trichloroacetic acid (TCA) and/or frequency-doubled Q-switched Nd:YAG laser therapy for an average of 6 months. Clinical evaluation and melasma severity were recorded using the melasma area and severity index (MASI) score.
RESULTS: The improvement score was significantly higher among the topically treated group compared with other lines of therapy (p<0.0001). No significant difference in improvement score was detected in the laser group compared with the peeling group. The epidermal type of melasma was also significantly improved compared with the dermal type (p<0.01).
CONCLUSION: Topical hydroquinone remains the most effective agent for the treatment of melasma in dark-skinned people with rare side effects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19340686     DOI: 10.1080/14764170902842549

Source DB:  PubMed          Journal:  J Cosmet Laser Ther        ISSN: 1476-4172            Impact factor:   2.247


  2 in total

Review 1.  Laser treatment of medical skin disease in women.

Authors:  C LaRosa; A Chiaravalloti; S Jinna; W Berger; J Finch
Journal:  Int J Womens Dermatol       Date:  2017-07-21

2.  Combination of Hydroquinone and Fractional CO2 Laser versus Hydroquinone Monotherapy in Melasma Treatment: A Randomized, Single-blinded, Split-face Clinical Trial.

Authors:  Sanaz Nourmohammadi Abadchi; Farahnaz Fatemi Naeini; Elham Beheshtian
Journal:  Indian J Dermatol       Date:  2019 Mar-Apr       Impact factor: 1.494

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.